Table 4– Decline in forced expiratory volume in 1 s (FEV1) from the European Community Respiratory Health Survey I to II, according to ADRB2 Gly16Arg genotypes, and stratified by inhaled corticosteroid (ICS) and long-acting β2-agonist (LABA) use#
ICS useLABA useFEV1 decline mL·yr−1
SubjectsGly/GlyGly/ArgArg/Argptrend
All asthmatics51921 (11–30)29 (201–38)36 (25–46)0.003
ICS nonusersNo27221 (8–34)31 (20–42)39 (25–53)0.007
ICS usersYes24817 (1–32)28 (13–42)31 (14–48)0.062
LABA nonusersNo43822 (12–33)31 (22–41)39 (27–50)0.004
LABA usersYes837 (33–20)18 (44– +9)18 (48– +12)0.338
ICS or LABA nonusersNoNo25824 (11–38)32 (21–44)40 (26–55)0.022
ICS nonusers + LABA usersNoYes14+13 (55– +81)47 (122– +28)25 (115– +66)0.228
ICS users + LABA nonusersYesNo17818 (0.7–36)30 (13–46)39 (19–59)0.028
ICS and LABA usersYesYes6810 (42– +22)17 (48– +14)10 (45– +25)0.92
  • Data are presented as n or mean (95% CI), unless otherwise stated. The p-value for the trend (ptrend) was calculated by linear regression assuming an additive model and modelling the categorical ADRB2 genotype variable as continuous. Bold indicates p-values that passed Bonferroni correction for multiple testing (p<0.05/9=0.0056). “+” indicates an increase (not a decline) in FEV1. The p-value for the interaction between Gly16Arg genotypes and ICS was p=0.9, between Gly16Arg genotypes and LABA was p=0.8, and between LABA and ICS was p=0.5. #: n=519; : linear regression models were adjusted for sex, age, height, current, former or never tobacco smoker and FEV1 at baseline (1991).